The ophthalmology small molecule API market is witnessing robust growth, driven by the increasing prevalence of ocular diseases, particularly age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and dry eye disease. As the global population ages, the demand for effective treatments for these chronic conditions is rising, propelling the market forward. Small molecule drugs offer advantages such as ease of administration, lower cost compared to biologics, and broader accessibility, making them highly attractive for both patients and healthcare systems.
The approval of novel small molecule drugs targeting various pathways in the eye, such as tyrosine kinase inhibitors for diabetic retinopathy and Rho kinase inhibitors for glaucoma, is expanding treatment options and improving patient outcomes. Furthermore, the growing trend of personalized medicine in ophthalmology is driving research into small molecules tailored to specific genetic and disease profiles.
